REVOLUTION MED. DL-0001
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more
Market Cap & Net Worth: REVOLUTION MED. DL-0001 (42Z)
REVOLUTION MED. DL-0001 (F:42Z) has a market capitalization of $16.37 Billion (€15.95 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #1252 globally and #88 in its home market, demonstrating a -2.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying REVOLUTION MED. DL-0001's stock price €82.50 by its total outstanding shares 193319805 (193.32 Million).
REVOLUTION MED. DL-0001 Market Cap History: 2020 to 2026
REVOLUTION MED. DL-0001's market capitalization history from 2020 to 2026. Data shows growth from $6.47 Billion to $16.37 Billion (21.07% CAGR).
REVOLUTION MED. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how REVOLUTION MED. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 42Z by Market Capitalization
Companies near REVOLUTION MED. DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to REVOLUTION MED. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
REVOLUTION MED. DL-0001 Historical Marketcap From 2020 to 2026
Between 2020 and today, REVOLUTION MED. DL-0001's market cap moved from $6.47 Billion to $ 16.37 Billion, with a yearly change of 21.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €16.37 Billion | +22.22% |
| 2025 | €13.39 Billion | +61.48% |
| 2024 | €8.29 Billion | +58.33% |
| 2023 | €5.24 Billion | +18.92% |
| 2022 | €4.41 Billion | -2.63% |
| 2021 | €4.52 Billion | -30.06% |
| 2020 | €6.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of REVOLUTION MED. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.37 Billion USD |
| MoneyControl | $16.37 Billion USD |
| MarketWatch | $16.37 Billion USD |
| marketcap.company | $16.37 Billion USD |
| Reuters | $16.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.